跳至主要内容
临床试验/NCT05547074
NCT05547074已完成不适用

Development and Validation of a New Prognostic Score Model Combining TNM Stage With Immune Risk Factors for Postoperative Pancreatic Ductal Adenocarcinoma

Zhejiang University1 个研究点 分布在 1 个国家目标入组 302 人开始时间: 2019年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
302
试验地点
1
主要终点
overall survival

研究概览

简要总结

The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to exert a profound impact on patients'clinical outcome. This study was aimed to develop a comprehensive and effective prognostic score model to predict prognosis and guide clinical management for postoperative PDAC patients.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Pathologically confirmed PDAC
  • Achievement of surgical resection (including radical or palliative surgery)

排除标准

  • Lost to follow-up
  • Simultaneous presence of other tumors
  • Died in three months after surgery

结局指标

主要结局

overall survival

时间窗: after pancreatic cancer surgery until october 31, 2020

the number of months from the date of surgery to the date of the last follow-up visit or time of death.

次要结局

  • disease-free survival disease-free survival disease-free survival disease-free survival(after pancreatic cancer surgery until october 31, 2020)

研究者

发起方
Zhejiang University
申办方类型
Other
责任方
Principal Investigator
主要研究者

TingBo Liang

Head of Hepatobiliary and Pancreatic Surgery

Zhejiang University

研究点 (1)

Loading locations...

相似试验